INS and Hypoglycemia: The results of DEVOTE demonstrated that insulin degludec was superior with regard to severe hypoglycaemia risk at equivalent glycaemic control compared with insulin glargine, thereby confirming observations from earlier studies including the open-label Phase 3a programme and the double-blind, crossover SWITCH trial in patients with type 2 diabetes [12, 13, 15].